Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Ongoing research exploring mechanisms of resistance to IMiDs in myeloma

Lawrence Boise • 28 Sep 2023
IMS 2023
Multiple Myeloma Lenalidomide Pomalidomide Thalidomide

Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, briefly discusses research exploring mechanisms of resistance to agents including lenalidomide, pomalidomide, and thalidomide, highlighting the role of the Ikaros protein. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lawrence Boise

0:49
The role of the tumor microenvironment in drug resistance in multiple myeloma
Lawrence Boise • 28 Sep 2023
Resistance mechanisms mediated by the microenvironment in multiple myeloma
Charlotte Pawlyn et al. • 15 Apr 2023
15:51
Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy
Lawrence Boise et al. • 27 Mar 2022
1:29
Venetoclax phase III trial disappointment
Lawrence Boise • 12 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals